Category: Chronic Pulmonary Disorders

Chronic Pulmonary Disorders

Global Respiratory Societies Mark World Bronchiectasis Day 2026

On July 1, international organizations aim to increase awareness and research for bronchiectasis to improve patient outcomes and healthcare access.

Chronic Pulmonary Disorders

ENA Respiratory Secures Two US Patents for COPD Therapy

ENA Respiratory received notices of allowance for two US patents covering its innate immune modulators and their application in preventing COPD exacerbations.

Chronic Pulmonary Disorders

Long-Term Data for Recurrent Respiratory Papillomatosis Therapy

Updated clinical data demonstrates that Papzimeos for adults with Recurrent Respiratory Papillomatosis (RRP) can maintain complete responses for more than four years.

Asthma

Tezepelumab Reduced Asthma Attacks

A new study shows tezepelumab (Tezspire) reduced asthma exacerbations by 70% across all patient subgroups, including smokers and those with comorbid conditions.

COPD

Nebulized Dual Bronchodilator Aero-007 Improved COPD Lung Function

AERO-007 demonstrated significant lung function improvements over 24 hours in patients with moderate-to-severe COPD.

Cystic fibrosis

COVID-19 Outcomes in Cystic Fibrosis Transplant Patients

New research indicates that baseline lung health is a stronger predictor of SARS-CoV-2 outcomes in cystic fibrosis transplantation patients than the time elapsed since transplantation.

Pulmonary Fibrosis

New Data on Inhaled Treprostinil for IPF

Data from clinical trials investigating treatments for pulmonary hypertension and pulmonary fibrosis will be highlighted at ATS 2026.

Allergies

Fatal Pediatric Anaphylaxis Linked to Delays in Epinephrine Treatment

New studies suggest that airway and breathing failures are the primary causes of death in childhood food anaphylaxis, requiring a shift in emergency management protocols.

Other Chronic Diseases

Alpha-1 Drug Candidate Superior to Standard Care

Phase 2 data for efdoralprin alfa demonstrate the recombinant protein maintains normal protein levels with less frequent dosing than current standards of care for patients with alpha-1 antitrypsin deficiency (AATD)-related emphysema.